Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,115.70 -7.30 (-0.65%)

Official Closing Price Updated: 4:10 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗

Today 13:20 EDT

The worst may be in the rearview mirror for the drugmaker.

Via The Motley Fool

Amgen Drops 10% on a Trial It Didn't Even Run ↗

Today 12:05 EDT

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Via MarketBeat

Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report ↗

Today 11:58 EDT

Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.

Via Benzinga

Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup ↗

Today 7:40 EDT

Via Chartmill

These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy. ↗

September 10, 2026

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

Via The Motley Fool

Topics ETFs Economy

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗

September 10, 2026

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

Via The Motley Fool

Topics ETFs

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗

September 10, 2026

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗

September 10, 2026

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

Via The Motley Fool

Topics ETFs

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗

September 10, 2026

This company aims to serve a market heading toward $100 billion.

Via The Motley Fool

CVS Health Eyes Margin Recovery, Cash Flow as 2027 Headwinds Loom ↗

September 10, 2026

CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on...

Via MarketBeat

Topics Earnings

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗

September 09, 2026

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.

Via The Motley Fool

Topics ETFs

Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 ↗

September 09, 2026

Hint: It's a good idea to buy the stock today.

Via The Motley Fool

Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗

September 08, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗

September 08, 2026

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Via The Motley Fool

Topics Intellectual Property

If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗

September 08, 2026

Low-cost index funds can be a ticket to prosperity for everyday investors.

Via The Motley Fool

Topics ETFs Economy

Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back ↗

September 08, 2026

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.

Via Benzinga

Topics ETFs

Why Is Eli Lilly Stock Falling Tuesday? ↗

September 08, 2026

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.

Via Benzinga

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗

September 08, 2026

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

Via Investor's Business Daily

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Via The Motley Fool

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock ↗

September 06, 2026

Is this big pharma stock still a buy for investors who aren't billionaires?

Via The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗

September 05, 2026

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

Via The Motley Fool

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years ↗

September 05, 2026

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

Via The Motley Fool

Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. ↗

September 05, 2026

Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.

Via The Motley Fool

MarketBeat Week in Review – 08/31 - 09/04 ↗

September 05, 2026

Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.

Via MarketBeat

Topics Artificial Intelligence Economy

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

If a Bear Market Is Coming, Is VOO or VTI the Safer Investment? ↗

September 04, 2026

You can't go wrong with either, but one has a key difference that gives it the edge.

Via The Motley Fool

Topics ETFs

2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗

September 04, 2026

You might regret ignoring these companies at current levels.

Via The Motley Fool

Topics Artificial Intelligence

Great News for Eli Lilly Stock Investors ↗

September 03, 2026

There is no end in sight for the company's incredible momentum.

Via The Motley Fool

Eli Lilly Just Announced a Major Acquisition. Here's What It Means. ↗

September 02, 2026

The drug giant added to its immunotherapy portfolio.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Eli Lilly (NY:LLY)

Headline News about Eli Lilly

Popular Pages